Jane L Liesveld

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint A phase I study of decitabine and rapamycin in relapsed/refractory AML
    Jane L Liesveld
    Department of Medicine, Division of Hematology Oncology, University of Rochester, Rochester, NY 14642, United States Electronic address
    Leuk Res 37:1622-7. 2013
  2. doi request reprint Clinical factors affecting engraftment and transfusion needs in SCT: a single-center retrospective analysis
    J Liesveld
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Bone Marrow Transplant 48:691-7. 2013
  3. doi request reprint Management of AML: who do we really cure?
    Jane Liesveld
    Hematology Oncology, JP Wilmot Cancer Center, University of Rochester Medical Center Strong Memorial Hospital, Rochester, NY 14642, USA
    Leuk Res 36:1475-80. 2012
  4. ncbi request reprint The hematopoietic stem cell in myelodysplasia
    Jane L Liesveld
    Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
    Stem Cells 22:590-9. 2004
  5. doi request reprint Mixed chimerism in SCT: conflict or peaceful coexistence?
    J L Liesveld
    Department of Medicine, The James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Bone Marrow Transplant 42:297-310. 2008
  6. ncbi request reprint Response of human CD34+ cells to CXC, CC, and CX3C chemokines: implications for cell migration and activation
    J L Liesveld
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Hematother Stem Cell Res 10:643-55. 2001
  7. ncbi request reprint Flavonoid effects on normal and leukemic cells
    Jane L Liesveld
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 27:517-27. 2003
  8. ncbi request reprint Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients
    Jane L Liesveld
    Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Biol Blood Marrow Transplant 8:662-5. 2002
  9. pmc Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells
    Jane L Liesveld
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 31:1553-63. 2007
  10. ncbi request reprint MIP-1alpha and TGF-beta production in CD34+ progenitor-stromal cell coculture systems: effects of progenitor isolation method and cell-cell contact
    J L Liesveld
    Department of Medicine, University of Rochester Cancer Center, Rochester, New York 14642, USA
    Blood Cells Mol Dis 26:261-75. 2000

Research Grants

Detail Information

Publications45

  1. doi request reprint A phase I study of decitabine and rapamycin in relapsed/refractory AML
    Jane L Liesveld
    Department of Medicine, Division of Hematology Oncology, University of Rochester, Rochester, NY 14642, United States Electronic address
    Leuk Res 37:1622-7. 2013
    ..This trial is registered at clinical trials.gov as NCT00861874...
  2. doi request reprint Clinical factors affecting engraftment and transfusion needs in SCT: a single-center retrospective analysis
    J Liesveld
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Bone Marrow Transplant 48:691-7. 2013
    ..Further studies are required to understand the means to minimize transfusions and potential related complications in SCT patients...
  3. doi request reprint Management of AML: who do we really cure?
    Jane Liesveld
    Hematology Oncology, JP Wilmot Cancer Center, University of Rochester Medical Center Strong Memorial Hospital, Rochester, NY 14642, USA
    Leuk Res 36:1475-80. 2012
    ....
  4. ncbi request reprint The hematopoietic stem cell in myelodysplasia
    Jane L Liesveld
    Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
    Stem Cells 22:590-9. 2004
    ....
  5. doi request reprint Mixed chimerism in SCT: conflict or peaceful coexistence?
    J L Liesveld
    Department of Medicine, The James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Bone Marrow Transplant 42:297-310. 2008
    ....
  6. ncbi request reprint Response of human CD34+ cells to CXC, CC, and CX3C chemokines: implications for cell migration and activation
    J L Liesveld
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Hematother Stem Cell Res 10:643-55. 2001
    ..Further understanding of this process may help elucidate the mechanism of stem cell mobilization and homing...
  7. ncbi request reprint Flavonoid effects on normal and leukemic cells
    Jane L Liesveld
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 27:517-27. 2003
    ..These flavonoid compounds might find use in various therapeutic settings in AML...
  8. ncbi request reprint Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients
    Jane L Liesveld
    Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Biol Blood Marrow Transplant 8:662-5. 2002
    ..This study demonstrates the feasibility and significant cost savings of using oral VAL for HSV prophylaxis...
  9. pmc Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells
    Jane L Liesveld
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Leuk Res 31:1553-63. 2007
    ..This work confirms that AML is influenced by the SDF-1alpha/CXCR4 axis and demonstrates that disruption of this axis by the bicyclam AMD3100 can influence AML microenvironmental interactions...
  10. ncbi request reprint MIP-1alpha and TGF-beta production in CD34+ progenitor-stromal cell coculture systems: effects of progenitor isolation method and cell-cell contact
    J L Liesveld
    Department of Medicine, University of Rochester Cancer Center, Rochester, New York 14642, USA
    Blood Cells Mol Dis 26:261-75. 2000
    ..The method of isolation of CD34+ progenitors may influence secretion of certain cytokines and chemokines...
  11. doi request reprint Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines
    Jane L Liesveld
    Department of Medicine, Hematology Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA jane
    Cancer Invest 29:439-50. 2011
    ..Combinations with arsenic trioxide, sorafenib, and cytarabine demonstrated synergistic in vitro effects in AML cell lines...
  12. doi request reprint Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML
    Alison R Walker
    James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    Leuk Res 32:1830-6. 2008
    ..To assess the efficacy of imatinib mesylate in combination with CLAG, a larger phase II trial is now planned...
  13. pmc Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data
    Duane C Hassane
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
    Blood 111:5654-62. 2008
    ..These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets...
  14. doi request reprint A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection
    Gordon L Phillips
    Hematology Oncology, University of Rochester Medical Center, James P Wilmot Cancer Center, Strong Memorial Hospital, Rochester, New York 14642, USA
    Biol Blood Marrow Transplant 17:1033-42. 2011
    ..A Phase II trial is planned...
  15. doi request reprint Delivery of apoptotic signal to rolling cancer cells: a novel biomimetic technique using immobilized TRAIL and E-selectin
    Kuldeepsinh Rana
    Department of Biomedical Engineering, Cornell University, Ithaca, New York, USA
    Biotechnol Bioeng 102:1692-702. 2009
    ..This represents the first demonstration of a novel biomimetic method to capture metastatic cells from circulation and deliver an apoptotic signal...
  16. ncbi request reprint P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow
    Srinivas D Narasipura
    Department of Biomedical Engineering, Wilmot Cancer Center, University of Rochester, Rochester, NY 14627, USA
    Clin Chem 54:77-85. 2008
    ..We have exploited this differential rolling behavior to capture and purify HSPCs from bone marrow by perfusing MNCs through selectin-coated microtubes...
  17. ncbi request reprint Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition
    Jane L Liesveld
    University of Rochester, University of Rochester Medical Center, Department of Medicine and the James P Wilmot Cancer Center, Rochester, NY 14642, USA
    Hematology 10:483-94. 2005
    ..These studies demonstrate that AML is subject to influence of endothelial cells and of agents such as bortezomib which have potential impact on AML interaction with the microenvironmental niche...
  18. pmc An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4427-35. 2007
    ..Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo...
  19. doi request reprint The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation
    Shahrukh Hashmi
    Mayo Clinic Transplant Center, Blood and Marrow Transplant Program, Mayo Clinic, Rochester, MN, United States
    Leuk Res 37:1052-6. 2013
    ..29, CI 0.091-0.886; intermediate HCT-CI HR=0.41, CI 0.226-0.752). Our findings suggest HCT-CI as an independent predictor of survival in the setting of RIC transplants...
  20. doi request reprint A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation
    Jane L Liesveld
    Department of Medicine, Hematology Oncology Division, University of Rochester Medical Center, Rochester, New York
    Biol Blood Marrow Transplant 19:1745-52. 2013
    ..We conclude that up to 27 days of once-daily dosing of eltrombopag after stem cell transplantation is well tolerated. ..
  21. pmc Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
    Monica L Guzman
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Blood 110:4436-44. 2007
    ..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations...
  22. pmc Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia
    Todd S Laughlin
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Mol Diagn 10:338-45. 2008
    ..Using a 100 nmol/L concentration of the LNA clamp, NPM1 mutations were detectable in a 10-fold excess of wild-type DNA. This assay may be valuable for screening disease specimens...
  23. pmc Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin
    Martin S Zand
    Division of Nephrology, University of Rochester Medical Center, 601 Elmwood Ave, Box 675, Rochester, NY 14642, USA
    Blood 107:2895-903. 2006
    ..We conclude that rATG is an effective agent for in vitro induction of apoptosis in multiple myeloma, and that exploratory clinical trials may be warranted...
  24. ncbi request reprint Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study
    J M Bennett
    University of Rochester Cancer Center, New York 14642, USA
    Am J Hematol 66:23-7. 2001
    ..55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients...
  25. ncbi request reprint Stem cell factor and stromal cell co-culture prevent apoptosis in a subculture of the megakaryoblastic cell line, UT-7
    J L Liesveld
    Department of Medicine, University of Rochester School of Medicine, NY 14642, USA
    Leuk Res 20:591-600. 1996
    ....
  26. ncbi request reprint TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors
    J Tang
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
    J Immunol 159:117-25. 1997
    ..These results indicate that TGF-beta is a significant negative regulator of stroma-dependent proliferation of early human lymphoid progenitors and acts in part by down-regulating stromal IL-7 secretion...
  27. ncbi request reprint Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients
    Christine M Szych
    Department of Pathology, University of Rochester, Strong Memorial Hospital, 601 Elmwood Avenue, P O Box 704, Rochester, NY 14642, USA
    Cancer Genet Cytogenet 174:132-7. 2007
    ..The impact of the isodicentric Philadelphia chromosomes on genomic instability, heterogeneity, and amplification of the Philadelphia chromosomes in IM-resistant patients is discussed...
  28. ncbi request reprint Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture
    Nicki Panoskaltsis
    The University of Rochester Medical Center, Department of Internal Medicine, Hematology Oncology Unit, Box 610, Rochester, NY 14642, USA
    Leuk Res 26:191-201. 2002
    ..Optimal growth and DC characteristics were obtained with GM-CSF, FL, and SCF in 3-5 day cultures, suggesting a practical strategy for the immunotherapy of leukemia...
  29. ncbi request reprint Investigating the feasibility of stem cell enrichment mediated by immobilized selectins
    Nichola Charles
    Department of Biomedical Engineering, University of Rochester, Rochester, New York, USA
    Biotechnol Prog 23:1463-72. 2007
    ..Optimal cell enrichment in immobilized selectin surfaces can be achieved within 10 min, much faster than most current commercially available systems...
  30. ncbi request reprint Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin
    J T Horan
    Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Bone Marrow Transplant 35:171-7. 2005
    ....
  31. ncbi request reprint Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis
    J L Liesveld
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
    Leukemia 17:1806-12. 2003
    ..These data suggest that myelosuppression with R115777 occurs largely at the intermediate to late progenitor stage of hematopoiesis and that cyclic use might avoid long-term marrow suppression...
  32. ncbi request reprint The effect of using music therapy with relaxation imagery in the management of patients undergoing bone marrow transplantation: a pilot feasibility study
    Olle Jane Z Sahler
    University of Rochester Medical Center, USA
    Altern Ther Health Med 9:70-4. 2003
    ..MAIN OUTCOME MEASURES: Pre/post music/relaxation imagery intervention measures of pain and nausea using a visual analog scale; determination of time-to-engraftment...
  33. ncbi request reprint Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation
    S Q Fu
    Blood and Marrow Stem Cell Transplant Program, Department of Internal Medicine and The James P Wilmot Cancer Center, University of Rochester, New York 14642, USA
    Blood Cells Mol Dis 28:315-21. 2002
    ..The CFU-GM/CD34+ ratio is an apparent predictor of earlier platelet engraftment, suggesting that the ratio reflects the engraftment potential of mobilized donor progenitor cells...
  34. pmc BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells
    Eleni D Lagadinou
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Cell Stem Cell 12:329-41. 2013
    ..Based on these findings, we propose a model wherein the unique physiology of ROS-low LSCs provides an opportunity for selective targeting via disruption of BCL-2-dependent oxidative phosphorylation...
  35. doi request reprint Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma
    Sughosh Dhakal
    Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Radiat Oncol Biol Phys 75:188-92. 2009
    ....
  36. ncbi request reprint Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials
    J T Horan
    Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Bone Marrow Transplant 32:293-8. 2003
    ..07 for the studies enrolling a smaller proportion. This finding substantiates results from previously published studies that have demonstrated a survival advantage with PBSCT limited to patients with advanced disease...
  37. ncbi request reprint Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants
    A P Rapoport
    University of Rochester Medical Center, Rochester, NY
    J Clin Oncol 17:2446-53. 1999
    ..To identify predictors of oral mucositis and gastrointestinal toxicity after high-dose therapy...
  38. ncbi request reprint What would Karl Landsteiner do? The ABO blood group and stem cell transplantation
    J M Heal
    Hematology Oncology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Bone Marrow Transplant 36:747-55. 2005
    ....
  39. ncbi request reprint Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report
    G L Phillips
    The James P Wilmot Cancer Center, BMT Program, Rochester, NY 14642, USA
    Semin Oncol 31:59-61. 2004
    ..Patient entry at the starting dose (ie, HD-MEL 140 mg/m2) has been completed without the development of severe regimen-related toxicities. This trial is ongoing...
  40. ncbi request reprint The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
    Neal Flomenberg
    Thomas Jefferson University, 125 S Ninth St, Ste 801 Sheridan Bldg, Philadelphia, PA 19107, USA
    Blood 106:1867-74. 2005
    ..All study objectives were met without significant toxicity. The results demonstrate that the combination of A + G is generally safe, effective, and superior to G alone for autologous HPC mobilization...
  41. pmc A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Blood 109:1387-94. 2007
    ..Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response...
  42. ncbi request reprint A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
    Jacob M Rowe
    Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Haifa 31096 Israel
    Blood 103:479-85. 2004
    ..Priming with hematopoietic growth factor did not improve response when compared with placebo. Furthermore, delaying induction therapy in older adults may lead to a lower complete remission rate...
  43. ncbi request reprint A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    Corey S Cutler
    International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226, USA
    Blood 104:579-85. 2004
    ..For low- and intermediate-1-risk MDS, delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated with maximal life expectancy...
  44. ncbi request reprint Acute promyelocytic leukemia-mobile and infiltrative
    Jane L Liesveld
    Leuk Res 31:5-7. 2007
  45. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...

Research Grants2

  1. Proteasome Inhibition in Myelodysplastic Syndromes
    Jane Liesveld; Fiscal Year: 2006
    ..These studies will define a potential therapeutic role for bortezomib in MDS and will aid in understanding the hematopoietic stem cell in these disorders. ..